| abstract |
The presently-disclosed subject matter relates to methods and systems for examining tumor samples, methods and systems for identifying subjects who are likely responders to treatment, and methods for treating cancer. In some embodiments, the presently-disclosed subject matter relates to determining expression of a major histocompatibility complex-II (MHC-II) molecule on a cell from a tumor sample, and further involving determining presence of tumor-infiltrating T cells in the tumor sample, determining the presence of tumor-infiltrating lymphocytes in the tumor sample, detecting chemokine expression in the tumor sample, and/or detecting TP53 mutations in the tumor sample. In some embodiments, the method involves treatment with an immunotherapeutic agent either alone or in combination with an MDM2 antagonist or an MEK inhibitor. |